Paul Hastings's Trading History
| NKTXNkarta | Jun 22, 2026 | CEO, Director | Uninformative Sell | 4.81K | $608.79K | |
| PCRXPacira Pharmaceuticals | Jun 13, 2024 | Director | Uninformative Sell | 24.97K | $463.03K | |
| OMEDOncoMed Pharma | Oct 12, 2017 | ― | Informative Sell | 5.93K | $308.71K | |
| TARAProtara Therapeutics | Oct 20, 2016 | Director | Uninformative Buy | ― | ― | |
| RLYPRelypsa Inc | Jun 23, 2016 | ― | Uninformative Buy | ― | $112.22K | |
| NVLNFNovelion Therapeutics | ― | ― | ― | $6.67K | ||
| ENGNenGene Holdings | ― | Director | ― | ― |
You May Also Like
Paul Hastings insider profile FAQ
What is the percentage of profitable transactions made by Paul Hastings?
The percentage of profitable transactions made by Paul Hastings is 60%.
What is the average return per transaction made by Paul Hastings?
The average return per transaction made by Paul Hastings is 19.30%.
What stocks does Paul Hastings hold?
Paul Hastings holds: NKTX, OMED, TARA, ENGN, PCRX, RLYP, NVLNF stocks.
What was Paul Hastings’s latest transaction?
Paul Hastings’s latest transaction was an Uninformative Sell of $4.81K.
What was Paul Hastings's most profitable transaction?
Paul Hastings’s most profitable transaction was an Informative Sell of NKTX stock on January 18, 2024. The return on the trade was 70.90%.
What is Paul Hastings's role in Nkarta?
Paul Hastings's role in Nkarta is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.